JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB146666

Quisqualic acid (mM/ml), group I mGlu agonist

Be the first to review this product! Submit a review

|

(0 Publication)

MW 189.13 Da, Purity >99%. Potent group I mGlu agonist and AMPA receptor agonist. Achieve your results faster with highly validated, pure and trusted compounds.

View Alternative Names

AMPA 1, AMPA 2, AMPA 3, AMPA 4, AMPA-selective glutamate receptor 1, AMPA-selective glutamate receptor 2, AMPA-selective glutamate receptor 3, AMPA-selective glutamate receptor 4, EEA3, Excitatory amino acid receptor 1, Excitatory amino acid receptor 2, Excitatory amino acid receptor 3, Excitatory amino acid receptor 4, Excitatory amino acid receptor 5, GLR 6, GLR 7, GLR5, GLUH1, GLUK3, GLUK6, GLUR, GLUR4C, GPRC1A, GPRC1E, GRIA1_HUMAN, GRIA2_HUMAN, GRIA3_HUMAN, GRIA4_HUMAN, GRIK, GRIK1_HUMAN, GRIK2 protein, GRIK2_HUMAN, GRIK3_HUMAN, GRIK4_HUMAN, GRIK5_HUMAN, GRM1-Alpha, GRM1_HUMAN, GRM5_HUMAN, GluA 4, GluA1, GluA2, GluA3, GluK2, GluK4, GluK5, GluR 7a, GluR-1, GluR-2, GluR-3, GluR-4, GluR-5, GluR-6, GluR-7, GluR-A, GluR-B, GluR-C, GluR-D, GluR-K1, GluR-K2, GluR-K3, GluRgamma2, Glutamate ionotropic receptor AMPA type subunit 3, Glutamate receptor, Glutamate receptor 1, Glutamate receptor 2, Glutamate receptor 3, Glutamate receptor 4, Glutamate receptor 5, Glutamate receptor 6, Glutamate receptor 7, Glutamate receptor C, Glutamate receptor KA 1precursor, Glutamate receptor KA-1, Glutamate receptor KA-2, Glutamate receptor ionotrophic AMPA 3, Glutamate receptor ionotrophic AMPA 4, Glutamate receptor ionotropic, Glutamate receptor ionotropic AMPA 1, Glutamate receptor ionotropic AMPA 2, Glutamate receptor ionotropic kainate 1, Glutamate receptor ionotropic kainate 2, Glutamate receptor ionotropic kainate 3, Glutamate receptor ionotropic kainate 4, Glutamate receptor ionotropic kainate 4 precursor, Glutamate receptor metabotropic 1, Glutamate receptor metabotropic 5, Glutamate receptor subunit 3, Glutamate receptor, ionotropic kainate 5 [Precursor], Glutamate receptor, ionotropic, AMPA 3, Glutamate receptor, ionotropic, kainate 5, Glutamate receptor, ionotropic, kainate 5 (gamma 2), HBGR1, HBGR2, Human glutamate receptor GLUR5, Ionotrophic Glutamate Receptor, Ionotropic Glutamate receptor 4, KA2, MGC118086, MGC133252, MGLU1, MRT6, MRX94, Metabotropic glutamate receptor 1, Metabotropic glutamate receptor 5, Metabotropic glutamate receptor 5 variant F, Metabotropic glutamate receptor 5 variant G, Metabotropic glutamate receptor 5 variant H, OTTHUMP00000045951, OTTHUMP00000096569, OTTHUMP00000160643, OTTHUMP00000165781, OTTHUMP00000224241, OTTHUMP00000224242, OTTHUMP00000224243, OTTHUMP00000231881, PPP1R86, Protein phosphatase 1 regulatory subunit 86, SCAR13, Smp_128940, bA487F5.1, dJ1171F9.1, glutamate receptor form A, glutamate receptor form B, glutamate receptor form C, glutamate receptor form D, glutamate receptor form E, iGlu5, ionotropic kainate 1, ionotropic kainate 2, ionotropic kainate 3, ionotropic kainate 4, ionotropic kainate 5, mGlu5, mGluR1, mGluR5

Key facts

CAS number

52809-07-1

Purity

>99%

Form

Solid

form

Molecular weight

189.13 Da

Molecular formula

C<sub>5</sub>H<sub>7</sub>N<sub>3</sub>O<sub>5</sub>

PubChem

40539

Nature

Synthetic

Biochemical name

Quisqualic acid

Biological description

Potent group I mGlu agonist and AMPA receptor agonist.

Canonical smiles

C(C(C(=O)O)N)N1C(=O)NC(=O)O1

Isomeric smiles

C([C@@H](C(=O)O)N)N1C(=O)NC(=O)O1

InChi

InChI=1S/C5H7N3O5/c6-2(3(9)10)1-8-4(11)7-5(12)13-8/h2H,1,6H2,(H,9,10)(H,7,11,12)/t2-/m0/s1

InChiKey

ASNFTDCKZKHJSW-REOHCLBHSA-N

IUPAC Name

(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Glutamate receptors are key components involved in synaptic transmission and neural plasticity. They consist of multiple subtypes including Ionotropic (AMPA NMDA Kainate) and Metabotropic (mGluR) receptors. Notable members include GluA1 GluA3 GluA4 GRIK2/GluK2 GRIK3/GluK3 GluK1 GluK5 and mGluR5. These receptors are located primarily in the central nervous system and are integral to the maintenance of fast excitatory synaptic transmission. These proteins such as GluA1 (AMPA receptor) have molecular masses varying between approximately 90 to 100 kDa and play distinct roles in responding to the neurotransmitter glutamate.
Biological function summary

These receptors drive important processes in neurocommunication and plasticity. They act in both ionotropic capacity mediating fast excitatory transmission through cation flows and metabotropic roles modulating signalling pathways via G-proteins. Receivers like GluA1 form tetrameric complexes facilitating synaptic responses and are important in learning and memory. Metabotropic variants such as mGluR1a and mGluR5 influence synaptic plasticity and development by modulating intracellular signalling cascades. Together these receptors are essential in transmitting the excitatory signals important for normal brain function.

Pathways

These receptors are integral to pathways such as the glutamatergic synapse and neurotrophin signalling pathways. They interact with proteins such as PSD-95 within postsynaptic density where AMPA and NMDA receptors play a synergistic role in synaptic strength. Their interaction allows the fine-tuning of synaptic responses. The Metabotropic receptors are linked to intracellular pathways impacting calcium signalling while the Kainate receptors contribute to the regulation of excitability and neurotransmitter release.

Abnormal functioning of these receptors links to several conditions including Alzheimer's disease and epilepsy. In Alzheimer's dysregulation of GluA1 and NMDA receptors can contribute to synaptic loss and cognitive decline. In epilepsy altered activity of Kainate receptors like GluK2 may lead to increased neuronal excitability and seizure propagation. Targeting these receptors can provide therapeutic strategies for managing these neurological disorders and improving patient outcomes.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com